11:45 AM EST - Cardiome Pharma Corp. : has submitted a Supplemental New Drug Submission (sNDS) to Health Canada's Therapeutic Products Directorate for AGGRASTAT® (tirofiban hydrochloride). The sNDS includes data to support: 1) High Dose Bolus administration of AGGRASTAT; and 2) an indication expansion for the reduction of major cardiovascular events in patients with acute myocardial infarction (STEMI) intended for primary PCI. Cardiome Pharma Corp.
shares T.COM are trading down $0.58 at $11.12.
